488 related articles for article (PubMed ID: 35085851)
1. Intranasal COVID-19 vaccines: From bench to bed.
Alu A; Chen L; Lei H; Wei Y; Tian X; Wei X
EBioMedicine; 2022 Feb; 76():103841. PubMed ID: 35085851
[TBL] [Abstract][Full Text] [Related]
2. Respiratory mucosal delivery of next-generation COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-2.
Afkhami S; D'Agostino MR; Zhang A; Stacey HD; Marzok A; Kang A; Singh R; Bavananthasivam J; Ye G; Luo X; Wang F; Ang JC; Zganiacz A; Sankar U; Kazhdan N; Koenig JFE; Phelps A; Gameiro SF; Tang S; Jordana M; Wan Y; Mossman KL; Jeyanathan M; Gillgrass A; Medina MFC; Smaill F; Lichty BD; Miller MS; Xing Z
Cell; 2022 Mar; 185(5):896-915.e19. PubMed ID: 35180381
[TBL] [Abstract][Full Text] [Related]
3. Oral Bacteria Combined with an Intranasal Vaccine Protect from Influenza A Virus and SARS-CoV-2 Infection.
Nagai M; Moriyama M; Ichinohe T
mBio; 2021 Aug; 12(4):e0159821. PubMed ID: 34399617
[TBL] [Abstract][Full Text] [Related]
4. Nasal prevention of SARS-CoV-2 infection by intranasal influenza-based boost vaccination in mouse models.
Zhou R; Wang P; Wong YC; Xu H; Lau SY; Liu L; Mok BW; Peng Q; Liu N; Woo KF; Deng S; Tam RC; Huang H; Zhang AJ; Zhou D; Zhou B; Chan CY; Du Z; Yang D; Au KK; Yuen KY; Chen H; Chen Z
EBioMedicine; 2022 Jan; 75():103762. PubMed ID: 34942445
[TBL] [Abstract][Full Text] [Related]
5. Toll-like Receptor-4 (TLR4) Agonist-Based Intranasal Nanovaccine Delivery System for Inducing Systemic and Mucosal Immunity.
Bakkari MA; Valiveti CK; Kaushik RS; Tummala H
Mol Pharm; 2021 Jun; 18(6):2233-2241. PubMed ID: 34010002
[TBL] [Abstract][Full Text] [Related]
6. Intranasal inoculation of an MVA-based vaccine induces IgA and protects the respiratory tract of hACE2 mice from SARS-CoV-2 infection.
Americo JL; Cotter CA; Earl PL; Liu R; Moss B
Proc Natl Acad Sci U S A; 2022 Jun; 119(24):e2202069119. PubMed ID: 35679343
[TBL] [Abstract][Full Text] [Related]
7. Intranasal vaccines for SARS-CoV-2: From challenges to potential in COVID-19 management.
Chavda VP; Vora LK; Pandya AK; Patravale VB
Drug Discov Today; 2021 Nov; 26(11):2619-2636. PubMed ID: 34332100
[TBL] [Abstract][Full Text] [Related]
8. Intranasal administration of a single dose of MVA-based vaccine candidates against COVID-19 induced local and systemic immune responses and protects mice from a lethal SARS-CoV-2 infection.
Pérez P; Astorgano D; Albericio G; Flores S; Sánchez-Cordón PJ; Luczkowiak J; Delgado R; Casasnovas JM; Esteban M; García-Arriaza J
Front Immunol; 2022; 13():995235. PubMed ID: 36172368
[TBL] [Abstract][Full Text] [Related]
9. Intranasal nanoemulsion adjuvanted S-2P vaccine demonstrates protection in hamsters and induces systemic, cell-mediated and mucosal immunity in mice.
Ganesan S; Acosta H; Brigolin C; Orange K; Trabbic K; Chen C; Lien CE; Lin YJ; Lin MY; Chuang YS; Fattom A; Bitko V
PLoS One; 2022; 17(11):e0272594. PubMed ID: 36322572
[TBL] [Abstract][Full Text] [Related]
10. Neutralizing-antibody-independent SARS-CoV-2 control correlated with intranasal-vaccine-induced CD8
Ishii H; Nomura T; Yamamoto H; Nishizawa M; Thu Hau TT; Harada S; Seki S; Nakamura-Hoshi M; Okazaki M; Daigen S; Kawana-Tachikawa A; Nagata N; Iwata-Yoshikawa N; Shiwa N; Suzuki T; Park ES; Ken M; Onodera T; Takahashi Y; Kusano K; Shimazaki R; Suzaki Y; Ami Y; Matano T
Cell Rep Med; 2022 Feb; 3(2):100520. PubMed ID: 35233545
[TBL] [Abstract][Full Text] [Related]
11. A single intranasal administration of AdCOVID protects against SARS-CoV-2 infection in the upper and lower respiratory tracts.
Schultz MD; Suschak JJ; Botta D; Silva-Sanchez A; King RG; Detchemendy TW; Meshram CD; Foote JB; Zhou F; Tipper JL; Zhang J; Harrod KS; Leal SM; Randall TD; Roberts MS; Georges B; Lund FE
Hum Vaccin Immunother; 2022 Nov; 18(6):2127292. PubMed ID: 36194255
[TBL] [Abstract][Full Text] [Related]
12. Peritoneal Administration of a Subunit Vaccine Encapsulated in a Nanodelivery System Not Only Augments Systemic Responses against SARS-CoV-2 but Also Stimulates Responses in the Respiratory Tract.
Jearanaiwitayakul T; Apichirapokey S; Chawengkirttikul R; Limthongkul J; Seesen M; Jakaew P; Trisiriwanich S; Sapsutthipas S; Sunintaboon P; Ubol S
Viruses; 2021 Nov; 13(11):. PubMed ID: 34835008
[TBL] [Abstract][Full Text] [Related]
13. Protective mucosal immunity against SARS-CoV-2 after heterologous systemic prime-mucosal boost immunization.
Lapuente D; Fuchs J; Willar J; Vieira Antão A; Eberlein V; Uhlig N; Issmail L; Schmidt A; Oltmanns F; Peter AS; Mueller-Schmucker S; Irrgang P; Fraedrich K; Cara A; Hoffmann M; Pöhlmann S; Ensser A; Pertl C; Willert T; Thirion C; Grunwald T; Überla K; Tenbusch M
Nat Commun; 2021 Nov; 12(1):6871. PubMed ID: 34836955
[TBL] [Abstract][Full Text] [Related]
14. Intranasal vaccination with a lentiviral vector protects against SARS-CoV-2 in preclinical animal models.
Ku MW; Bourgine M; Authié P; Lopez J; Nemirov K; Moncoq F; Noirat A; Vesin B; Nevo F; Blanc C; Souque P; Tabbal H; Simon E; Hardy D; Le Dudal M; Guinet F; Fiette L; Mouquet H; Anna F; Martin A; Escriou N; Majlessi L; Charneau P
Cell Host Microbe; 2021 Feb; 29(2):236-249.e6. PubMed ID: 33357418
[TBL] [Abstract][Full Text] [Related]
15. Intranasal delivery of an adenovirus-vector vaccine co-expressing a modified spike protein and a genetic adjuvant confers lasting mucosal immunity against SARS-CoV-2.
Jung HE; Ku KB; Kang BH; Park JH; Kim HC; Kim KD; Lee HK
Antiviral Res; 2023 Aug; 216():105656. PubMed ID: 37327877
[TBL] [Abstract][Full Text] [Related]
16. The Bacterial Mucosal Immunotherapy MV130 Protects Against SARS-CoV-2 Infection and Improves COVID-19 Vaccines Immunogenicity.
Del Fresno C; García-Arriaza J; Martínez-Cano S; Heras-Murillo I; Jarit-Cabanillas A; Amores-Iniesta J; Brandi P; Dunphy G; Suay-Corredera C; Pricolo MR; Vicente N; López-Perrote A; Cabezudo S; González-Corpas A; Llorca O; Alegre-Cebollada J; Garaigorta U; Gastaminza P; Esteban M; Sancho D
Front Immunol; 2021; 12():748103. PubMed ID: 34867974
[TBL] [Abstract][Full Text] [Related]
17. Unadjuvanted intranasal spike vaccine elicits protective mucosal immunity against sarbecoviruses.
Mao T; Israelow B; Peña-Hernández MA; Suberi A; Zhou L; Luyten S; Reschke M; Dong H; Homer RJ; Saltzman WM; Iwasaki A
Science; 2022 Nov; 378(6622):eabo2523. PubMed ID: 36302057
[TBL] [Abstract][Full Text] [Related]
18. Prospects for mucosal vaccine: shutting the door on SARS-CoV-2.
Mudgal R; Nehul S; Tomar S
Hum Vaccin Immunother; 2020 Dec; 16(12):2921-2931. PubMed ID: 32931361
[TBL] [Abstract][Full Text] [Related]
19. Sterilizing Immunity against COVID-19: Developing Helper T cells I and II activating vaccines is imperative.
Kyei-Barffour I; Addo SA; Aninagyei E; Ghartey-Kwansah G; Acheampong DO
Biomed Pharmacother; 2021 Dec; 144():112282. PubMed ID: 34624675
[TBL] [Abstract][Full Text] [Related]
20. Safety, immunogenicity, and protection provided by unadjuvanted and adjuvanted formulations of a recombinant plant-derived virus-like particle vaccine candidate for COVID-19 in nonhuman primates.
Pillet S; Arunachalam PS; Andreani G; Golden N; Fontenot J; Aye PP; Röltgen K; Lehmicke G; Gobeil P; Dubé C; Trépanier S; Charland N; D'Aoust MA; Russell-Lodrigue K; Monjure C; Blair RV; Boyd SD; Bohm RP; Rappaport J; Villinger F; Landry N; Pulendran B; Ward BJ
Cell Mol Immunol; 2022 Feb; 19(2):222-233. PubMed ID: 34983950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
